ADAPTIVE BIOTECHNOLOGIES CORPORATION Net Income (Loss) Available to Common Stockholders, Basic
ADAPTIVE BIOTECHNOLOGIES CORPORATION (ADPT) reported Net Income (Loss) Available to Common Stockholders, Basic of -$207.28 million for the 12-month period ending 2021-12-31, per its 10-K filed 2022-02-15.
Discontinued › Income Statement
us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic · last filed 2022-02-15
- ADAPTIVE BIOTECHNOLOGIES CORPORATION net income (loss) available to common stockholders, basic for the quarter ending 2020-12-31 was -$44.57M.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION net income (loss) available to common stockholders, basic for the quarter ending 2020-09-30 was -$36.72M.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION net income (loss) available to common stockholders, basic for the quarter ending 2020-06-30 was -$33.53M.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION net income (loss) available to common stockholders, basic for the quarter ending 2020-03-31 was -$31.40M.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION net income (loss) available to common stockholders, basic for fiscal 2021 was -$207.28M.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION net income (loss) available to common stockholders, basic for fiscal 2020 was -$146.23M.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION net income (loss) available to common stockholders, basic for fiscal 2019 was -$69.57M.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION net income (loss) available to common stockholders, basic for fiscal 2018 was -$46.34M.
| Period end | Net Income (Loss) Available to Common Stockholders, Basic 3 month | Net Income (Loss) Available to Common Stockholders, Basic 6 month | Net Income (Loss) Available to Common Stockholders, Basic 9 month | Net Income (Loss) Available to Common Stockholders, Basic 12 month |
|---|---|---|---|---|
| 2021-12-31 | -$207.28M 10-K · filed 2022-02-15 | |||
| 2020-12-31 | -$44.57M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-15 | -$81.29M derived: sum of 2 quarters · filed 2022-02-15 | -$114.82M derived: sum of 3 quarters · filed 2022-02-15 | -$146.23M 10-K · filed 2022-02-15 |
| 2020-09-30 | -$36.72M 10-Q · filed 2020-11-10 | -$70.25M derived: sum of 2 quarters · filed 2020-11-10 | -$101.66M 10-Q · filed 2020-11-10 | -$122.27M derived: sum of 4 quarters · filed 2022-02-15 |
| 2020-06-30 | -$33.53M 10-Q · filed 2020-08-10 | -$64.94M 10-Q · filed 2020-08-10 | -$85.55M derived: sum of 3 quarters · filed 2022-02-15 | -$99.50M derived: sum of 4 quarters · filed 2022-02-15 |
| 2020-03-31 | -$31.40M 10-Q · filed 2020-05-12 | -$52.01M derived: sum of 2 quarters · filed 2022-02-15 | -$65.96M derived: sum of 3 quarters · filed 2022-02-15 | -$82.33M derived: sum of 4 quarters · filed 2022-02-15 |
| 2019-12-31 | -$20.61M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-15 | -$34.56M derived: sum of 2 quarters · filed 2022-02-15 | -$50.93M derived: sum of 3 quarters · filed 2022-02-15 | -$69.57M 10-K · filed 2022-02-15 |
| 2019-09-30 | -$13.95M 10-Q · filed 2020-11-10 | -$30.32M derived: sum of 2 quarters · filed 2020-11-10 | -$48.96M 10-Q · filed 2020-11-10 | -$62.13M derived: sum of 4 quarters · filed 2021-02-24 |
| 2019-06-30 | -$16.37M 10-Q · filed 2020-08-10 | -$35.01M 10-Q · filed 2020-08-10 | -$48.18M derived: sum of 3 quarters · filed 2021-02-24 | -$56.47M derived: sum of 4 quarters · filed 2021-02-24 |
| 2019-03-31 | -$18.64M 10-Q · filed 2020-05-12 | -$31.81M derived: sum of 2 quarters · filed 2021-02-24 | -$40.10M derived: sum of 3 quarters · filed 2021-02-24 | -$52.60M derived: sum of 4 quarters · filed 2021-02-24 |
| 2018-12-31 | -$13.17M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-24 | -$21.46M derived: sum of 2 quarters · filed 2021-02-24 | -$33.96M derived: sum of 3 quarters · filed 2021-02-24 | -$46.34M 10-K · filed 2021-02-24 |
| 2018-09-30 | -$8.30M 10-Q · filed 2019-11-12 | -$20.79M derived: sum of 2 quarters · filed 2019-11-12 | -$33.18M 10-Q · filed 2019-11-12 | |
| 2018-06-30 | -$12.49M 10-Q · filed 2019-08-13 | -$24.88M 10-Q · filed 2019-08-13 | ||
| 2017-12-31 | -$42.70M 10-K · filed 2020-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Greenland Mines Ltd (GRML) | United States | $2.362B |